AVO.L Regulatory News (AVO)

ADVANCED ONCOTHERAPY Plc

("Advanced Oncotherapy" or "the Company")

Issue of Equity

Advanced Oncotherapy (AIM: AVO) announces that it has conditionally placed 15,625,000 new ordinary shares (the "New Ordinary Shares") of the Company at a subscription price of 3.2 pence per New Ordinary Share to raise £0.5 million before expenses. The shares have been placed with three institutional investors.

Application will be made for the New Ordinary Shares to be admitted to trading on AIM and it is expected that trading will commence on or about 12 November 2013. The New Ordinary Shares will rank pari passu in all aspects with the existing ordinary shares of the Company. On admission, the total number of ordinary shares in issue will be 604,441,502.

For further information, please visit www.advancedoncotherapy.comor contact:

About Advanced Oncotherapy Plc

1. AVO is a provider of radiotherapy services that harnesses the best in modern technology. As a result, we offer cancer patients affordable access to innovative treatments with proven better health outcomes.

2. AVO's acquisition of ADAM, a company spin off from CERN (The Large Hadron Collider), focuses on the development of a proprietary radiation technology called LIGHT. This technology offers patients and providers the benefits of proton beam therapy at significantly reduced capital and running costs.

3. AVO's subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT). This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient. It is currently available in the UK from Spire Healthcare and BMI Healthcare Hospitals.

-ends-